Want to see IPSC full AI Analyst Report?
IPSC Stock Chart & Stats
$2.60
<$0.01(0.47%)
At close: 4:00 PM EST
$2.60
<$0.01(0.47%)
Day’s Range― - ―
52-Week Range$0.44 - $3.04
Previous CloseN/A
Volume712.78K
Average Volume (3M)880.90K
Market Cap
$441.87M
Enterprise Value$191.76M
Total Cash (Recent Filing)$134.80M
Total Debt (Recent Filing)$48.02M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding180,354,810
10 Day Avg. Volume884,271
30 Day Avg. Volume880,900
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.42
Enterprise Value/Ebitda-2.13
Forecast
1Y Price Target
$5.67Price Target Upside117.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Allogeneic IPSC PlatformCentury’s iPSC-derived allogeneic NK and T-cell approach establishes an off-the-shelf manufacturing model that can scale across multiple indications. Structurally, this reduces per-patient manufacturing complexity versus autologous therapies and enables platform reuse, supporting long-term commercial potential if clinical efficacy is proven.
Balance Sheet FlexibilityThe company’s modest leverage (low debt-to-equity) provides durable financial flexibility, lowering fixed financing costs and preserving capacity to fund R&D and manufacturing scale-up. This balance sheet strength is important for capital-intensive cell therapy programs and cushions operations while programs advance.
Pipeline Diversification & ManufacturingAdvancing CNTY-813 with durable preclinical efficacy, an established Phase 1 manufacturing process, and a planned IND (Q4 2026) represents a structural expansion into diabetes. Demonstrated manufacturing consistency and cryopreservation stability indicate readiness to scale clinical programs and diversify the company’s addressable markets beyond oncology.
Bears Say
Persistent Cash BurnOperating and free cash flow have been negative across most reported periods and in the TTM, indicating persistent cash burn. This structural cash consumption forces reliance on external funding or partnerships to sustain development, limiting strategic flexibility and increasing the likelihood of dilutive or costly financing until commercial revenues emerge.
Heavily Loss-making; Volatile RevenueThe company is structurally loss-making with deeply negative margins and volatile revenue, including TTM revenue dropping to zero and negative gross profit. Persistent unprofitability undermines the ability to self-fund development, prolongs dependence on external capital, and raises execution risk before any sustainable commercial revenue stream exists.
Reliance On Equity Financing / Dilution RiskShareholder approval to expand authorized shares and the active ATM program reflect a structural reliance on equity markets for funding. While this preserves runway, it raises enduring dilution risk and can erode per-share economics for existing holders unless development success leads to profitable, recurring revenues that offset issuance-related dilution.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics, Inc.’s price range in the past 12 months?
Century Therapeutics, Inc. lowest stock price was $0.43 and its highest was $3.04 in the past 12 months.
What is Century Therapeutics, Inc.’s market cap?
Century Therapeutics, Inc.’s market cap is $441.87M.
When is Century Therapeutics, Inc.’s upcoming earnings report date?
Century Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 36 days.
How were Century Therapeutics, Inc.’s earnings last quarter?
Century Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.048.
Is Century Therapeutics, Inc. overvalued?
According to Wall Street analysts Century Therapeutics, Inc.’s price is currently Undervalued.
Does Century Therapeutics, Inc. pay dividends?
Century Therapeutics, Inc. does not currently pay dividends.
What is Century Therapeutics, Inc.’s EPS estimate?
Century Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Century Therapeutics, Inc. have?
Century Therapeutics, Inc. has 180,354,810 shares outstanding.
What happened to Century Therapeutics, Inc.’s price movement after its last earnings report?
Century Therapeutics, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -0.437%.
Which hedge fund is a major shareholder of Century Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IPSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (117.95% Upside)
$5.67 (117.95% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 33.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
365.25%
12-Months-Change
Fundamentals
Return on Equity
-53.23%
Trailing 12-Months
Asset Growth
3.47%
Trailing 12-Months
Company Description
Century Therapeutics, Inc.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$5.67
▲(117.95% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
3.31% Insiders
3.55% Mutual Funds
58.78% Other Institutional Investors
28.31% Public Companies and
Individual Investors